{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:26:01Z","timestamp":1790641561879,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005042","name":"University Hospital Saint-Luc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ard.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:58:36Z","timestamp":1762552716000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["How good enough are the new therapies for lupus nephritis? A narrative review and a position paper"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-083X","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric A.","family":"Houssiau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.10.004_bib0001","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/art.40512","article-title":"Brief report: Lupus \u2013 an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015","volume":"70","author":"Yen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.10.004_bib0002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/ard.8.2.97","article-title":"The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report","volume":"8","author":"Hench","year":"1949","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0003","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0004","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.10.004_bib0005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0006","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0007","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","article-title":"Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0008","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.10.004_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0010","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.40079","article-title":"Brief report: the Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-M\u00fcllerian hormone","volume":"69","author":"Tamirou","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.10.004_bib0011","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0012","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0013","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0016","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.10.004_bib0017","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.10.004_bib0018","first-page":"677","article-title":"Why will lupus nephritis trials not fail anymore?","volume":"56","author":"Houssiau","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.10.004_bib0019","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomised, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.10.004_bib0021","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA-1): a double-blind, randomized, multicenter, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.10.004_bib0022","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/art.43209","article-title":"Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies","volume":"77","author":"Rovin","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.10.004_bib0023","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0024","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ard.2025.10.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000533","article-title":"Absence of renal remission portends poor long-term kidney outcomes in lupus nephritis","volume":"8","author":"Pirson","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0026","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","article-title":"Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis","volume":"59","author":"Parodis","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.ard.2025.10.004_bib0027","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.10.004_bib0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"2025 EULAR recommendations for the management of SLE with kidney involvement","volume":"83","author":"Fanouriakis","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0029","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial","volume":"50","author":"Houssiau","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.10.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000689","article-title":"Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis","volume":"9","author":"Gatto","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0031","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.kint.2021.09.012","article-title":"The lupus nephritis management renaissance","volume":"101","author":"Mejia-Vilet","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.10.004_bib0032","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort","volume":"67","author":"Dall-Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.10.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0034","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of glucocorticoid dose on complete response, serious infections, and mortality during initial therapy of lupus nephritis: a systematic review and meta-analysis of the control arms of randomized controlled trials","volume":"76","author":"Figueroa-Parra","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.10.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001428","article-title":"Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database","volume":"12","author":"Arnaud","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0036","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0037","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfk073","article-title":"Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up","volume":"21","author":"Moroni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ard.2025.10.004_bib0038","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentric randomized controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0039","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ekir.2024.01.016","article-title":"Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with lupus nephritis","volume":"9","author":"Gatto","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ard.2025.10.004_bib0040","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0041","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0042","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0043","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ard.2025.05.101","article-title":"OP0079 Clinical, cellular kinetics, pharmacodynamics and biomarker data up to 12 months after YTB323 (rapcabtagene autoleucel); a rapidly manufactured CD19 CAR-T therapy, from an open-label, phase 1\/2 study in severe refractory SLE","volume":"84","author":"Morand","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0044","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ard.2025.05.096","article-title":"OP0074 Preliminary results of CD19\/BCMA dual-targeting FasTCAR-T cells GC012F (AZD0120) in patients with refractory systemic lupus erythematosus-an open-label, single-arm study","volume":"884","author":"Wu","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ard.2025.05.214","article-title":"OP0202 RESET-SLE: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB anti-CD19 CAR T cell therapy in non-renal SLE and lupus nephritis","volume":"84","author":"Sheikh","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0047","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomized, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.10.004_bib0048","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0049","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/annrheumdis-2018-213485","article-title":"Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis","volume":"77","author":"Pamfil","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0050","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.10.004_bib0051","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0052","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Tobias","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0053","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-Targeted T-cell-engager therapy fir autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0054","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratifies, biopsy-driven, multicenter, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.10.004_bib0055","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ard.2025.10.004_bib0056","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1038\/s41467-025-60987-9","article-title":"Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis","volume":"16","author":"Lewis","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ard.2025.10.004_bib0057","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.172569","article-title":"Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis","volume":"9","author":"Fava","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ard.2025.10.004_bib0058","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.2019121285","article-title":"Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis","volume":"31","author":"Mejia-Vilet","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.10.004_bib0059","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/art.42023","article-title":"Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis","volume":"74","author":"Fava","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.10.004_bib0060","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.42941","article-title":"Urinary biomarker panel to predict the probability of histologically active lupus nephritis (abstract)","volume":"76","author":"Fava","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.10.004_bib0061","doi-asserted-by":"crossref","first-page":"i30","DOI":"10.1093\/rheumatology\/keac530","article-title":"Improving access to SLE therapies in low and middle-income countries","volume":"62","author":"Mendoza-Pinto","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.10.004_bib0062","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded humanitarian aid program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725044358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:26:23Z","timestamp":1779942383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725044358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0003496725044358"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.004","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How good enough are the new therapies for lupus nephritis? A narrative review and a position paper","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.07.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}